Gilead Sciences (GILD) 106.96 $GILD
J&J to Sell Sugar Substitute Splenda to Heartland Food
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 4:05PM CDT
Johnson & Johnson (JNJ) has agreed to sell its low-calorie sweetener brand, Splenda, to privately held Heartland Food Products Group.
JNJ: 95.11 (+4.38), GILD: 106.96 (+4.40), AMAG: 63.26 (+4.30), REGN: 535.47 (+36.45)
Results From the AMBITION Study of First-Line Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension Published in The New England Journal of Medicine
Business Wire - Wed Aug 26, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMBrIsentan and Tadalafil in patients with pulmonary arterial hypertensION). In AMBITION, conducted in collaboration with GlaxoSmithKline (GSK), combination therapy with Letairis(R) (ambrisentan) and tadalafil reduced the risk of clinical failure by 50 percent compared to the pooled Letairis and tadalafil monotherapy arm (hazard ratio = 0.50; 95 percent CI: 0.35, 0.72; p<0.001). These data were published in The New England Journal of Medicine.
GILD: 106.96 (+4.40), GSK: 40.47 (+1.06)
Novartis' (NVS) Promacta Label Further Expanded in U.S.
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 3:45PM CDT
Novartis (NVS) with partner Ligand (LGND) announced that the FDA has approved the use of Promacta in children between 1 to 6 years of age with chronic ITP.
GILD: 106.96 (+4.40), LGND: 90.89 (+4.83), GSK: 40.47 (+1.06), NVS: 97.13 (+1.99)
Eli Lilly's Alimta Patent Upheld by U.S. District Court
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 3:35PM CDT
Eli Lilly and Company announced that it has received a favorable ruling in a lawsuit related to the infringement of vitamin regimen patent for Alimta.
AGN: 305.98 (+15.35), GILD: 106.96 (+4.40), TEVA: 64.82 (+0.61), LLY: 81.10 (+2.84)
Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 3:30PM CDT
Sarepta's (SRPT) Duchenne muscular dystrophy candidate, eteplirsen, is under priority review in the U.S.; approval could come by Feb 26, 2016.
BMRN: 128.10 (+6.96), GILD: 106.96 (+4.40), SRPT: 34.17 (+1.59), REGN: 535.47 (+36.45)
You Can't Keep Volatility Down Forever
at The Street - Wed Aug 26, 1:00PM CDT
We saw this coming, but there's more to the recent turmoil than China.
BIIB: 298.25 (+16.51), HACK: 27.14 (+0.93), GILD: 106.96 (+4.40), BHP: 34.08 (+1.16), LH: 117.80 (+3.04), AMGN: 153.98 (+8.79)
Global Opthalmic Therapeutic Market 2015 Report With Forecasts to 2019
M2 - Wed Aug 26, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kswdmq/global_opthalmic) has announced the addition of the "Global Opthalmic Therapeutic Market 2015-2019" report to their offering. According to the report, the global ophthalmic therapeutic market will grow at a CAGR of 6.53% over the period 2014-2019. The incidence of eye diseases is increasing worldwide, particularly in industrialized and middle-income countries. Changing dietary habits, unhealthy lifestyles, and increased use of electronic equipment such as computers, TVs, and videogames affect normal eyesight. Smoking increases an individual's chances of developing AMD by 2-3 times. Similarly, individuals with diets high in fat, cholesterol, and sugar and low in antioxidants are more likely to be affected by AMD. People with diabetes have a higher risk of being affected by diabetic retinopathy and macular edema. The population of people with diabetes is likely to increase from 382 million in 2013 to 592 million by 2035, leading to a rise in individuals with DME. The total number of cases of diabetic retinopathy is expected to increase from 4.89 million in 2012 to 7.17 million by 2022. The WHO classifies glaucoma as the second leading cause of visual impairment in the world, affecting about 285 million people worldwide. Further, the report states that the limited public awareness of eye diseases restricts the market growth. Key Topics Covered - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Pipeline Analysis - Market Landscape - Market Segmentation by Disease Type - Market Segmentation by Route of Administration - Market Segmentation by Molecule Type - Market Segmentation by Dosage Form - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and Their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and Their Impact - Vendor Landscape - Key Vendor Analysis Companies Mentioned Partial list of the 60 companies featured in this comprehensive report: - Acadia Pharmaceuticals - Actavis - Bayer - BCN Peptides - Carl Zeiss Meditec - Eleven Biotherapeutics - F. Hoffmann-La Roche - Falcon Pharmaceuticals - Gilead Sciences - GlaxoSmithKline - Icon Bioscience - Lexicon Pharmaceuticals - Merck - Novartis - Ohr Pharmaceutical - PanOptica - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Seikagaku - StemCells - ThromboGenics - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/ks..._opthalmic
ACAD: 36.38 (+2.24), LXRX: 12.07 (+0.05), GILD: 106.96 (+4.40), MRK: 54.42 (+3.25), OHRP: 2.63 (+0.15), GSK: 40.47 (+1.06), REGN: 535.47 (+36.45), NVS: 97.13 (+1.99)
Celldex (CLDX) Shows Strength: Stock Adds 8.2% in Session
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 8:46AM CDT
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as its shares rose over 8% on the day.
GILD: 106.96 (+4.40), CLDX: 14.36 (+0.39)
Acorda Therapeutics (ACOR) Jumps: Stock Moves 8.3% Higher
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 8:46AM CDT
Acorda Therapeutics (ACOR) was a big mover last session with its shares rising over 8% on the day.
GILD: 106.96 (+4.40), ACOR: 31.96 (+0.59)
Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global
M2 - Wed Aug 26, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwjwh6/hepatitis_c) has announced the addition of the "Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global" report to their offering. Market for Hepatitis C drugs has grown with a phenomenal rate of more than US$ 13 Billion, in the year 2014 compared to 2013. In the last two years a couple of new drugs have been introduced in the market which has become a huge success and they have captured maximum market share of the Hepatitis C market. Gilead currently dominates the multi-billion dollar Hepatitis C market, but AbbVie has been trying to increase its market share since U.S. regulators approved the marketing of its Viekira Pak. Drug makers are already focusing on introducing new drugs in the market as several drugs are standing in the pipeline. Hepatitis C Drugs is anticipated to be a rosy market for future period. Key Topics Covered - Executive Summary - Hepatitis C Drugs - Market & Forecast - Hepatitis C - Approved Drugs Sales & Forecast - Hepatitis C - Pipeline Drugs Sales Forecast - Hepatitis C - Deals & Acquisitions - Hepatitis C - Company Wise Clinical Trials Analysis Companies Mentioned - AbbVie - Bristol-Myers Squibb (BMS) - Gilead Sciences - Merck & Co. - Tibotec/Janssen Therapeutics For more information visit http://www.researchandmarkets.com/research/mw...epatitis_c
GILD: 106.96 (+4.40), MRK: 54.42 (+3.25), BMY: 60.03 (+2.15)
What Makes CoLucid Pharmaceuticals (CLCD) a Strong Sell?
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 7:40AM CDT
CoLucid Pharmaceuticals (CLCD) has witnessed a significant price decline in the past one month, and it has lately seen negative earnings estimate revisions as well.
CLCD: 6.23 (-0.11), GILD: 106.96 (+4.40)
4 Notable Stocks Still Green After Late Tuesday Sell-Off
Ryan McQueeney - Zacks Investment Research - Tue Aug 25, 5:41PM CDT
Who is still green after the market's afternoon sell-off?
NFLX: 110.13 (+8.61), UA: 90.76 (+3.74), GILD: 106.96 (+4.40), FB: 87.19 (+4.19)
Nasdaq Slips into Correction: 4 Stocks Stand Tall
Zacks Equity Research - Zacks Investment Research - Tue Aug 25, 4:31PM CDT
Quality stocks will always remain in favor despite the currently volatility . And who wouldn't like to build positions in them when these are available at an attractive bargain price.
NFLX: 110.13 (+8.61), ESRX: 84.10 (+3.18), ERIC: 9.70 (+0.27), GILD: 106.96 (+4.40), FB: 87.19 (+4.19), GOOGL: 659.74 (+47.27), MSFT: 42.71 (+2.24), AAPL: 109.69 (+5.95), PDLI: 5.39 (+0.09)
Medivation to Gain Global Rights to BioMarin's Talazoparib
Zacks Equity Research - Zacks Investment Research - Tue Aug 25, 4:00PM CDT
Medivation (MDVN) enters into an asset purchase agreement with BioMarin to acquire worldwide rights to BioMarin's talazoparib.
MDVN: 89.71 (+3.59), BMRN: 128.10 (+6.96), GILD: 106.96 (+4.40), AZN: 31.13 (+0.85)
AstraZeneca, Peregrine Team Up for Immuno-Oncology Study
Zacks Equity Research - Zacks Investment Research - Tue Aug 25, 3:30PM CDT
AstraZeneca (AZN) inked a clinical trial collaboration with Peregrine to evaluate bavituximab plus durvalumab in a phase I/Ib study.
INO: 6.80 (+0.21), GILD: 106.96 (+4.40), AZN: 31.13 (+0.85), PPHM: 1.14 (-0.02)
U.S. Stocks Rally, But Is Now Time to Buy?
at The Street - Tue Aug 25, 2:36PM CDT
The CNBC ‘Fast Money’ traders debate whether it's time to dive into stocks now that the market seems to have stabilized.
KR: 35.08 (+1.42), JPM: 62.91 (+3.00), GILD: 106.96 (+4.40), UTX: 91.56 (+2.76), FB: 87.19 (+4.19), C: 52.28 (+2.40), XOM: 72.50 (+3.79), DIS: 99.23 (+3.34), WFC: 52.30 (+2.28), OXY: 67.15 (+1.40), AFL: 56.92 (+1.69), AAPL: 109.69 (+5.95)
Gilead Leads 4 Drugmakers In Top Sector Performers
at Investor's Business Daily - Tue Aug 25, 2:06PM CDT
Following a three-day plummet, stocks popped Tuesday, with several top drugmakers like Gilead making a climb. Today's Screen of the Day focuses on Top Sector Performers. Over half of a stock's price move can be attributed to the strength of its...
AGN: 305.98 (+15.35), VRX: 227.24 (+7.16), GILD: 106.96 (+4.40), SCMP: 24.55 (+0.61), TEVA: 64.82 (+0.61)
Bouncing Biotech? 3 Stocks To Buy
Todd Campbell, The Motley Fool - Motley Fool - Tue Aug 25, 11:15AM CDT
Source: Flickr user stockmonkeys.com Although uncertainty may be the only market certainty, investors embracing long term investing have made money by buying big market drops time and time again. Given the market's nose-dive this month, that could...
GILD: 106.96 (+4.40), SNY: 49.13 (+1.30), REGN: 535.47 (+36.45), CELG: 119.23 (+6.53)
J&J to Sell Sugar Substitute Splenda to Heartland Food
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 4:05PM CDT
Johnson & Johnson (JNJ) has agreed to sell its low-calorie sweetener brand, Splenda, to privately held Heartland Food Products Group.
JNJ: 95.11 (+4.38), GILD: 106.96 (+4.40), AMAG: 63.26 (+4.30), REGN: 535.47 (+36.45)
Results From the AMBITION Study of First-Line Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension Published in The New England Journal of Medicine
Business Wire - Wed Aug 26, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMBrIsentan and Tadalafil in patients with pulmonary arterial hypertensION). In AMBITION, conducted in collaboration with GlaxoSmithKline (GSK), combination therapy with Letairis(R) (ambrisentan) and tadalafil reduced the risk of clinical failure by 50 percent compared to the pooled Letairis and tadalafil monotherapy arm (hazard ratio = 0.50; 95 percent CI: 0.35, 0.72; p<0.001). These data were published in The New England Journal of Medicine.
GILD: 106.96 (+4.40), GSK: 40.47 (+1.06)
Novartis' (NVS) Promacta Label Further Expanded in U.S.
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 3:45PM CDT
Novartis (NVS) with partner Ligand (LGND) announced that the FDA has approved the use of Promacta in children between 1 to 6 years of age with chronic ITP.
GILD: 106.96 (+4.40), LGND: 90.89 (+4.83), GSK: 40.47 (+1.06), NVS: 97.13 (+1.99)
Eli Lilly's Alimta Patent Upheld by U.S. District Court
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 3:35PM CDT
Eli Lilly and Company announced that it has received a favorable ruling in a lawsuit related to the infringement of vitamin regimen patent for Alimta.
AGN: 305.98 (+15.35), GILD: 106.96 (+4.40), TEVA: 64.82 (+0.61), LLY: 81.10 (+2.84)
Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 3:30PM CDT
Sarepta's (SRPT) Duchenne muscular dystrophy candidate, eteplirsen, is under priority review in the U.S.; approval could come by Feb 26, 2016.
BMRN: 128.10 (+6.96), GILD: 106.96 (+4.40), SRPT: 34.17 (+1.59), REGN: 535.47 (+36.45)
You Can't Keep Volatility Down Forever
at The Street - Wed Aug 26, 1:00PM CDT
We saw this coming, but there's more to the recent turmoil than China.
BIIB: 298.25 (+16.51), HACK: 27.14 (+0.93), GILD: 106.96 (+4.40), BHP: 34.08 (+1.16), LH: 117.80 (+3.04), AMGN: 153.98 (+8.79)
Global Opthalmic Therapeutic Market 2015 Report With Forecasts to 2019
M2 - Wed Aug 26, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kswdmq/global_opthalmic) has announced the addition of the "Global Opthalmic Therapeutic Market 2015-2019" report to their offering. According to the report, the global ophthalmic therapeutic market will grow at a CAGR of 6.53% over the period 2014-2019. The incidence of eye diseases is increasing worldwide, particularly in industrialized and middle-income countries. Changing dietary habits, unhealthy lifestyles, and increased use of electronic equipment such as computers, TVs, and videogames affect normal eyesight. Smoking increases an individual's chances of developing AMD by 2-3 times. Similarly, individuals with diets high in fat, cholesterol, and sugar and low in antioxidants are more likely to be affected by AMD. People with diabetes have a higher risk of being affected by diabetic retinopathy and macular edema. The population of people with diabetes is likely to increase from 382 million in 2013 to 592 million by 2035, leading to a rise in individuals with DME. The total number of cases of diabetic retinopathy is expected to increase from 4.89 million in 2012 to 7.17 million by 2022. The WHO classifies glaucoma as the second leading cause of visual impairment in the world, affecting about 285 million people worldwide. Further, the report states that the limited public awareness of eye diseases restricts the market growth. Key Topics Covered - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Pipeline Analysis - Market Landscape - Market Segmentation by Disease Type - Market Segmentation by Route of Administration - Market Segmentation by Molecule Type - Market Segmentation by Dosage Form - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and Their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and Their Impact - Vendor Landscape - Key Vendor Analysis Companies Mentioned Partial list of the 60 companies featured in this comprehensive report: - Acadia Pharmaceuticals - Actavis - Bayer - BCN Peptides - Carl Zeiss Meditec - Eleven Biotherapeutics - F. Hoffmann-La Roche - Falcon Pharmaceuticals - Gilead Sciences - GlaxoSmithKline - Icon Bioscience - Lexicon Pharmaceuticals - Merck - Novartis - Ohr Pharmaceutical - PanOptica - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Seikagaku - StemCells - ThromboGenics - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/ks..._opthalmic
ACAD: 36.38 (+2.24), LXRX: 12.07 (+0.05), GILD: 106.96 (+4.40), MRK: 54.42 (+3.25), OHRP: 2.63 (+0.15), GSK: 40.47 (+1.06), REGN: 535.47 (+36.45), NVS: 97.13 (+1.99)
Celldex (CLDX) Shows Strength: Stock Adds 8.2% in Session
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 8:46AM CDT
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as its shares rose over 8% on the day.
GILD: 106.96 (+4.40), CLDX: 14.36 (+0.39)
Acorda Therapeutics (ACOR) Jumps: Stock Moves 8.3% Higher
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 8:46AM CDT
Acorda Therapeutics (ACOR) was a big mover last session with its shares rising over 8% on the day.
GILD: 106.96 (+4.40), ACOR: 31.96 (+0.59)
Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global
M2 - Wed Aug 26, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwjwh6/hepatitis_c) has announced the addition of the "Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global" report to their offering. Market for Hepatitis C drugs has grown with a phenomenal rate of more than US$ 13 Billion, in the year 2014 compared to 2013. In the last two years a couple of new drugs have been introduced in the market which has become a huge success and they have captured maximum market share of the Hepatitis C market. Gilead currently dominates the multi-billion dollar Hepatitis C market, but AbbVie has been trying to increase its market share since U.S. regulators approved the marketing of its Viekira Pak. Drug makers are already focusing on introducing new drugs in the market as several drugs are standing in the pipeline. Hepatitis C Drugs is anticipated to be a rosy market for future period. Key Topics Covered - Executive Summary - Hepatitis C Drugs - Market & Forecast - Hepatitis C - Approved Drugs Sales & Forecast - Hepatitis C - Pipeline Drugs Sales Forecast - Hepatitis C - Deals & Acquisitions - Hepatitis C - Company Wise Clinical Trials Analysis Companies Mentioned - AbbVie - Bristol-Myers Squibb (BMS) - Gilead Sciences - Merck & Co. - Tibotec/Janssen Therapeutics For more information visit http://www.researchandmarkets.com/research/mw...epatitis_c
GILD: 106.96 (+4.40), MRK: 54.42 (+3.25), BMY: 60.03 (+2.15)
What Makes CoLucid Pharmaceuticals (CLCD) a Strong Sell?
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 7:40AM CDT
CoLucid Pharmaceuticals (CLCD) has witnessed a significant price decline in the past one month, and it has lately seen negative earnings estimate revisions as well.
CLCD: 6.23 (-0.11), GILD: 106.96 (+4.40)
4 Notable Stocks Still Green After Late Tuesday Sell-Off
Ryan McQueeney - Zacks Investment Research - Tue Aug 25, 5:41PM CDT
Who is still green after the market's afternoon sell-off?
NFLX: 110.13 (+8.61), UA: 90.76 (+3.74), GILD: 106.96 (+4.40), FB: 87.19 (+4.19)
Nasdaq Slips into Correction: 4 Stocks Stand Tall
Zacks Equity Research - Zacks Investment Research - Tue Aug 25, 4:31PM CDT
Quality stocks will always remain in favor despite the currently volatility . And who wouldn't like to build positions in them when these are available at an attractive bargain price.
NFLX: 110.13 (+8.61), ESRX: 84.10 (+3.18), ERIC: 9.70 (+0.27), GILD: 106.96 (+4.40), FB: 87.19 (+4.19), GOOGL: 659.74 (+47.27), MSFT: 42.71 (+2.24), AAPL: 109.69 (+5.95), PDLI: 5.39 (+0.09)
Medivation to Gain Global Rights to BioMarin's Talazoparib
Zacks Equity Research - Zacks Investment Research - Tue Aug 25, 4:00PM CDT
Medivation (MDVN) enters into an asset purchase agreement with BioMarin to acquire worldwide rights to BioMarin's talazoparib.
MDVN: 89.71 (+3.59), BMRN: 128.10 (+6.96), GILD: 106.96 (+4.40), AZN: 31.13 (+0.85)
AstraZeneca, Peregrine Team Up for Immuno-Oncology Study
Zacks Equity Research - Zacks Investment Research - Tue Aug 25, 3:30PM CDT
AstraZeneca (AZN) inked a clinical trial collaboration with Peregrine to evaluate bavituximab plus durvalumab in a phase I/Ib study.
INO: 6.80 (+0.21), GILD: 106.96 (+4.40), AZN: 31.13 (+0.85), PPHM: 1.14 (-0.02)
U.S. Stocks Rally, But Is Now Time to Buy?
at The Street - Tue Aug 25, 2:36PM CDT
The CNBC ‘Fast Money’ traders debate whether it's time to dive into stocks now that the market seems to have stabilized.
KR: 35.08 (+1.42), JPM: 62.91 (+3.00), GILD: 106.96 (+4.40), UTX: 91.56 (+2.76), FB: 87.19 (+4.19), C: 52.28 (+2.40), XOM: 72.50 (+3.79), DIS: 99.23 (+3.34), WFC: 52.30 (+2.28), OXY: 67.15 (+1.40), AFL: 56.92 (+1.69), AAPL: 109.69 (+5.95)
Gilead Leads 4 Drugmakers In Top Sector Performers
at Investor's Business Daily - Tue Aug 25, 2:06PM CDT
Following a three-day plummet, stocks popped Tuesday, with several top drugmakers like Gilead making a climb. Today's Screen of the Day focuses on Top Sector Performers. Over half of a stock's price move can be attributed to the strength of its...
AGN: 305.98 (+15.35), VRX: 227.24 (+7.16), GILD: 106.96 (+4.40), SCMP: 24.55 (+0.61), TEVA: 64.82 (+0.61)
Bouncing Biotech? 3 Stocks To Buy
Todd Campbell, The Motley Fool - Motley Fool - Tue Aug 25, 11:15AM CDT
Source: Flickr user stockmonkeys.com Although uncertainty may be the only market certainty, investors embracing long term investing have made money by buying big market drops time and time again. Given the market's nose-dive this month, that could...
GILD: 106.96 (+4.40), SNY: 49.13 (+1.30), REGN: 535.47 (+36.45), CELG: 119.23 (+6.53)
